Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses

NCT00705835 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00705835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00705835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2003
Completion date
January 31, 2008
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer